Strategic backing Novelstar is a Fosun Pharma subsidiary focusing on NDA and ANDA products with advanced drug delivery systems, presenting a channel to access Fosun’s global network, regulatory expertise, and potential co-development or contract manufacturing opportunities.

Small team agility With a lean headcount (2-10 employees) and proximity to New Jersey, there is a strong need for scalable partnerships in formulation development, clinical support, regulatory filing, and manufacturing services to accelerate product launches.

NDA ANDA focus The emphasis on NDA and ANDA development signals opportunities for late-stage formulation improvements, bioequivalence studies, packaging optimization, and API-to-dosage form transitions in collaboration with CROs and CDMOs.

Financial potential Current revenue range indicates early growth stage with potential for revenue expansion through strategic partnerships, licensing deals, and joint ventures aligned with Fosun’s global footprint and portfolio.

Market positioning As a small, specialized unit within a large multinational, Novelstar can offer niche capabilities in targeted therapeutic areas, enabling focused outreach to pharmaceutical companies seeking specialized delivery systems and rapid market entry.